Elevance Health Inc (ELV)
Official siteHEALTHCARE • HEALTHCARE PLANS • NYSE
Market Cap: $92.84B
Last updated: Nov 17, 2026 at 11:05 AM ET
Elevance Health Inc (ELV) Financials: Revenue, Profit and Cash Flow
Elevance Health reported revenue of $199.13B for the fiscal year ended Dec 31, 2025, up 12.6% from the year before. That year, net income was $5.66B with a net margin of 2.8%, operating cash flow was $4.29B and free cash flow was $3.17B. The quarter ended Sep 30, 2026 had revenue of $51.43B and net income of $1.34B.
Revenue and Margins
The operating margin was 4.1% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $84.86B, a compound annual rate of 9.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $199.13B | +12.6% | 14.9% | 4.1% | 2.8% |
| Dec 2024 | $176.81B | +3.2% | 5.4% | 5.0% | 3.4% |
| Dec 2023 | $171.34B | +9.4% | 17.3% | 5.1% | 3.5% |
| Dec 2022 | $156.59B | +13.0% | 17.2% | 5.4% | 3.8% |
| Dec 2021 | $138.64B | +13.8% | 18.2% | 6.3% | 4.4% |
| Dec 2020 | $121.87B | +16.9% | 20.4% | 5.8% | 3.8% |
| Dec 2019 | $104.21B | +13.1% | 19.6% | 6.5% | 4.6% |
| Dec 2018 | $92.11B | +2.3% | 21.9% | 6.3% | 4.1% |
| Dec 2017 | $90.04B | +6.1% | 19.8% | 5.5% | 4.3% |
| Dec 2016 | $84.86B | N/A | 21.2% | 6.2% | 2.9% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 5.2% from the year before. In the quarter ended Sep 2026, net income rose 12.6% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $199.13B | $176.81B | $171.34B | $156.59B | $138.64B | $121.87B | $104.21B | $92.11B | $90.04B | $84.86B |
| Cost of revenue | $169.40B | $167.34B | $141.62B | $129.68B | $113.47B | $97.00B | $83.78B | $71.89B | $72.24B | $66.83B |
| Gross profit | $29.72B | $9.47B | $29.72B | $26.92B | $25.17B | $24.87B | $20.43B | $20.21B | $17.80B | $18.03B |
| Operating income | $8.11B | $8.89B | $8.74B | $8.45B | $8.79B | $7.06B | $6.73B | $5.83B | $4.99B | $5.28B |
| Net income | $5.66B | $5.97B | $5.99B | $5.89B | $6.15B | $4.57B | $4.81B | $3.75B | $3.84B | $2.47B |
| EBITDA | $9.66B | $10.48B | $10.49B | $10.13B | $10.10B | $8.21B | $7.87B | $6.96B | $5.88B | $6.19B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $51.43B | $50.47B | $50.18B | $49.75B | $50.71B | $49.78B | $48.89B | $45.44B | $45.15B | $43.65B | $42.58B | $42.65B |
| Gross profit | $8.01B | $7.96B | $9.10B | $6.16B | $7.19B | $7.78B | $8.60B | -$8.83B | $1.83B | $8.25B | $8.21B | $11.29B |
| Operating income | $2.15B | $2.30B | $2.66B | $581.00M | $1.76B | $2.63B | $3.14B | $946.00M | $1.71B | $3.03B | $3.20B | $1.26B |
| Net income | $1.34B | $1.45B | $1.76B | $546.00M | $1.19B | $1.74B | $2.18B | $413.00M | $1.01B | $2.30B | $2.25B | $831.00M |
Balance Sheet
As of Dec 2025, total debt of $32.05B exceeded cash and equivalents by $22.55B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $121.49B | $116.89B | $108.93B | $102.75B | $97.46B | $86.61B | $77.45B | $71.57B | $70.54B | $65.08B |
| Current assets | $63.00B | $58.94B | $60.03B | $55.62B | $51.12B | $45.75B | $39.03B | $34.32B | $36.26B | $34.31B |
| Cash and equivalents | $9.49B | $8.29B | $6.53B | $7.39B | $4.88B | $5.74B | $4.94B | $3.93B | $3.61B | $4.08B |
| Total liabilities | $77.47B | $75.46B | $69.52B | $66.42B | $61.29B | $53.42B | $45.73B | $43.03B | $44.04B | $39.98B |
| Short-term debt | $1.25B | $2.01B | $1.87B | $1.76B | $1.87B | $700.00M | $2.30B | $1.99B | $2.55B | $1.37B |
| Long-term debt | $30.80B | $29.22B | $23.25B | $22.35B | $21.16B | $19.34B | $17.79B | $17.22B | $17.38B | $14.36B |
| Shareholder equity | $43.88B | $41.31B | $39.31B | $36.24B | $36.09B | $33.20B | $31.73B | $28.54B | $26.50B | $25.10B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $127.80B | $126.44B | $125.83B | $121.49B | $122.75B | $121.94B | $119.72B | $116.89B | $116.53B | $112.99B | $111.89B | $108.93B |
| Total liabilities | $83.01B | $81.42B | $81.78B | $77.47B | $78.67B | $78.09B | $77.10B | $75.46B | $72.65B | $70.69B | $71.18B | $69.52B |
| Cash and equivalents | $10.35B | $10.23B | $9.66B | $9.49B | $8.71B | $8.56B | $7.50B | $8.29B | $7.87B | $6.50B | $6.23B | $6.53B |
| Shareholder equity | $44.68B | $44.88B | $43.90B | $43.88B | $43.95B | $43.72B | $42.50B | $41.31B | $43.77B | $42.19B | $40.61B | $39.31B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 73.9% of operating cash flow. Dividends and share repurchases together came to 130.3% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.29B | $5.81B | $8.06B | $8.40B | $8.36B | $10.69B | $6.06B | $3.83B | $4.18B | $3.27B |
| Capital expenditures | $1.12B | $1.26B | $1.30B | $1.15B | $1.09B | $1.02B | $1.08B | $1.21B | $791.00M | $584.00M |
| Free cash flow | $3.17B | $4.55B | $6.76B | $7.25B | $7.28B | $9.67B | $4.98B | $2.62B | $3.39B | $2.69B |
| Dividends paid | $1.53B | $1.51B | $1.40B | $1.23B | $1.10B | $954.00M | $818.00M | $776.00M | $705.00M | $684.00M |
| Share repurchases | $2.60B | $2.90B | $2.68B | $2.32B | $1.90B | $2.70B | $1.70B | $1.69B | $2.00B | $0 |
| Investing cash flow | -$1.34B | -$5.17B | -$5.57B | -$4.56B | -$9.64B | -$7.32B | -$2.79B | -$1.26B | -$5.08B | -$514.00M |
| Financing cash flow | -$1.74B | $1.19B | -$3.35B | -$1.32B | $423.00M | -$2.57B | -$2.27B | -$2.24B | $427.00M | -$799.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.27B | $1.91B | $4.33B | $84.00M | $1.14B | $2.05B | $1.02B | $706.00M | $2.68B | $447.00M | $1.98B | -$2.97B |
| Capital expenditures | $267.00M | $287.00M | $235.00M | $293.00M | $360.00M | $267.00M | $196.00M | $322.00M | $332.00M | $323.00M | $279.00M | $326.00M |
| Free cash flow | $1.00B | $1.63B | $4.10B | -$209.00M | $775.00M | $1.79B | $821.00M | $384.00M | $2.35B | $124.00M | $1.70B | -$3.30B |
Frequently Asked Questions About ELV
What is Elevance Health's annual revenue?
Elevance Health reported revenue of $199.13B for the fiscal year ended Dec 31, 2025.
How fast is Elevance Health's revenue growing?
Revenue was up 12.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 8.3%.
Is Elevance Health profitable?
Yes. Elevance Health reported net income of $5.66B for the fiscal year ended Dec 31, 2025, with a net margin of 2.8%.
How much free cash flow does ELV generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $4.29B minus capital expenditures of $1.12B produced free cash flow of $3.17B.
How much debt does Elevance Health have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $30.80B, short-term debt of $1.25B and cash and equivalents of $9.49B.
ELV pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts